Trial Profile
A Multicenter Phase II Trial of Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tavokinogene telseplasmid (Primary)
- Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome
- Focus Therapeutic Use
- Sponsors OncoSec Medical
- 02 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 09 Apr 2014 Planned number of patients changed from 27 to 34.